These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 37777636)

  • 1. Osteolytic lesion as initial presentation in FIP1L1-PDGFRA-rearranged myeloid/lymphoid neoplasm with eosinophilia: a case report.
    Lv Y; Yao X; Ling Q; Suo S; Wang J; Zhao S; Gao X; Tong H; Jin J; Zhang X; Yu W
    Ann Hematol; 2024 Jan; 103(1):357-360. PubMed ID: 37777636
    [No Abstract]   [Full Text] [Related]  

  • 2. A challenging diagnosis of myeloid/lymphoid neoplasm with eosinophilia and FIP1L1::PDGFRA rearrangement.
    Coltro G; Santi R
    Blood; 2023 May; 141(20):2541. PubMed ID: 37200055
    [No Abstract]   [Full Text] [Related]  

  • 3. Next generation sequencing of myeloid neoplasms with eosinophilia harboring the FIP1L1-PDGFRA mutation.
    Pardanani A; Lasho T; Barraco D; Patnaik M; Elala Y; Tefferi A
    Am J Hematol; 2016 Mar; 91(3):E10-1. PubMed ID: 26663400
    [No Abstract]   [Full Text] [Related]  

  • 4. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy.
    Pardanani A; Ketterling RP; Brockman SR; Flynn HC; Paternoster SF; Shearer BM; Reeder TL; Li CY; Cross NC; Cools J; Gilliland DG; Dewald GW; Tefferi A
    Blood; 2003 Nov; 102(9):3093-6. PubMed ID: 12842979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib discontinuation for hypereosinophilic syndrome harboring the FIP1L1-PDGFRA transcript.
    Helbig G; Soja A; Świderska A; Hus M; Kyrcz-Krzemień S
    Leuk Lymphoma; 2016; 57(3):708-10. PubMed ID: 26430910
    [No Abstract]   [Full Text] [Related]  

  • 6. Progressive multifocal leukoencephalopathy responsive to withdrawal of imatinib in a patient with FIP1L1-PDGFRA positive myeloid neoplasm.
    Blum S; Dunet V; Comoli P; Tirefort Y; Chalandon Y; Opota O; Comte D; Spertini O; Livio F; Brouland JP; Du Pasquier R
    Leuk Lymphoma; 2020 Sep; 61(9):2226-2229. PubMed ID: 32364409
    [No Abstract]   [Full Text] [Related]  

  • 7. [Acute myeloid leukemia with FIP1L1-PDGFRA fusion gene treated with imatinib: a case report and literature review].
    Fan JC; You WW; Liu HX; Cai Y; Du X; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2020 Dec; 41(12):1044-1046. PubMed ID: 33445855
    [No Abstract]   [Full Text] [Related]  

  • 8. Myeloid Neoplasm With Eosinophilia and FIP1L1-PDGFRA Rearrangement Treated With Imatinib Mesylate: A Pediatric Case With Long-term Follow-up.
    Srinivasan A; Scordino T; Baker A
    J Pediatr Hematol Oncol; 2019 May; 41(4):334-335. PubMed ID: 30807397
    [No Abstract]   [Full Text] [Related]  

  • 9. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia.
    Pardanani A; Brockman SR; Paternoster SF; Flynn HC; Ketterling RP; Lasho TL; Ho CL; Li CY; Dewald GW; Tefferi A
    Blood; 2004 Nov; 104(10):3038-45. PubMed ID: 15284118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical features of hypereosinophilic syndrome: FIP1L1-PDGFRA fusion gene-positive disease is a distinct clinical entity with myeloproliferative features and a poor response to corticosteroid.
    Miyazawa K; Kakazu N; Ohyashiki K
    Int J Hematol; 2007 Jan; 85(1):5-10. PubMed ID: 17261495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintenance therapy with imatinib appears necessary despite molecular remission in FIP1L1-PDGFRA fusion gene positive hypereosinophilic disorder.
    Ng HJ; Tan DC; Yiu RC; How GF
    Leuk Res; 2008 Jan; 32(1):169-71. PubMed ID: 17544504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transient macular erythema with eosinophilia in a patient carrying the FIP1L1-PDGFRA fusion gene.
    Yahara H; Satoh T; Hashimoto T; Yokozeki H
    Br J Dermatol; 2007 Dec; 157(6):1284-7. PubMed ID: 17916194
    [No Abstract]   [Full Text] [Related]  

  • 13. Myocarditis, kidney injury, and hypereosinophilia: FIP1L1-PDGFRA-positive myeloid/lymphoid neoplasm with eosinophilia.
    Reid SE; Patel SA
    Blood; 2021 Sep; 138(12):1086. PubMed ID: 34554219
    [No Abstract]   [Full Text] [Related]  

  • 14. Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome.
    Helbig G; Kyrcz-Krzemień S
    Am J Hematol; 2014 Jan; 89(1):115. PubMed ID: 24009127
    [No Abstract]   [Full Text] [Related]  

  • 15. A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome.
    Salemi S; Yousefi S; Simon D; Schmid I; Moretti L; Scapozza L; Simon HU
    Allergy; 2009 Jun; 64(6):913-8. PubMed ID: 19210352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of FIP1L1-PDGFRA fusion by FISH.
    Ma ES; Wong KF; Wong CL; Siu LL
    Br J Haematol; 2007 Aug; 138(3):279. PubMed ID: 17542982
    [No Abstract]   [Full Text] [Related]  

  • 17. Marked eosinophilic atypia in a patient with asthma and myeloid/lymphoid neoplasm with FIP1L1::PDGFRA fusion.
    Deb PQ; Li L
    Br J Haematol; 2024 Jul; 205(1):14. PubMed ID: 38685615
    [No Abstract]   [Full Text] [Related]  

  • 18. Rapid reversion of eosinophilic gastroenteritis associated with FIP1L1-PDGFRA fusion after targeted therapy with imatinib.
    Pitini V; Sturniolo G; Cavallari V; Arrigo C
    Br J Haematol; 2006 Jan; 132(2):123. PubMed ID: 16398645
    [No Abstract]   [Full Text] [Related]  

  • 19. Imatinib for the treatment of hypereosinophilic syndromes.
    Helbig G
    Expert Rev Clin Immunol; 2018 Feb; 14(2):163-170. PubMed ID: 29303368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature.
    Pardanani A; Ketterling RP; Li CY; Patnaik MM; Wolanskyj AP; Elliott MA; Camoriano JK; Butterfield JH; Dewald GW; Tefferi A
    Leuk Res; 2006 Aug; 30(8):965-70. PubMed ID: 16406016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.